rituximab,epcoritamab
janssen,abbvie,biogen,roche,genmab
['epcore nhl-2', 'lymphoma', 'rituximab', 'epcoritamab', 'epcore,nhl,2', 'lymsm', 'nhl', 'follicular']
findings from an arm of the epcore nhl-2 trial showed promising antitumor activity in patients with relapsed or refractory follicular #lymphoma on subcutaneous epcoritamab combined with #rituximab and #lenalidomide. #asco22 #lymsm #fl 
Oncology news and insights from leading researchers and cancer centers.